122 related articles for article (PubMed ID: 37012199)
1. Sequential provocation of Ekbom's syndrome and acute mania following AstraZeneca COVID-19 vaccination.
Chang FY; Chen PA; Siao WH; Chen YC
Asian J Psychiatr; 2023 May; 83():103569. PubMed ID: 37012199
[TBL] [Abstract][Full Text] [Related]
2. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Voysey M; Costa Clemens SA; Madhi SA; Weckx LY; Folegatti PM; Aley PK; Angus B; Baillie VL; Barnabas SL; Bhorat QE; Bibi S; Briner C; Cicconi P; Clutterbuck EA; Collins AM; Cutland CL; Darton TC; Dheda K; Dold C; Duncan CJA; Emary KRW; Ewer KJ; Flaxman A; Fairlie L; Faust SN; Feng S; Ferreira DM; Finn A; Galiza E; Goodman AL; Green CM; Green CA; Greenland M; Hill C; Hill HC; Hirsch I; Izu A; Jenkin D; Joe CCD; Kerridge S; Koen A; Kwatra G; Lazarus R; Libri V; Lillie PJ; Marchevsky NG; Marshall RP; Mendes AVA; Milan EP; Minassian AM; McGregor A; Mujadidi YF; Nana A; Padayachee SD; Phillips DJ; Pittella A; Plested E; Pollock KM; Ramasamy MN; Ritchie AJ; Robinson H; Schwarzbold AV; Smith A; Song R; Snape MD; Sprinz E; Sutherland RK; Thomson EC; Török ME; Toshner M; Turner DPJ; Vekemans J; Villafana TL; White T; Williams CJ; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ;
Lancet; 2021 Mar; 397(10277):881-891. PubMed ID: 33617777
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
Li G; Cappuccini F; Marchevsky NG; Aley PK; Aley R; Anslow R; Bibi S; Cathie K; Clutterbuck E; Faust SN; Feng S; Heath PT; Kerridge S; Lelliott A; Mujadidi Y; Ng KF; Rhead S; Roberts H; Robinson H; Roderick MR; Singh N; Smith D; Snape MD; Song R; Tang K; Yao A; Liu X; Lambe T; Pollard AJ;
Lancet; 2022 Jun; 399(10342):2212-2225. PubMed ID: 35691324
[TBL] [Abstract][Full Text] [Related]
4. Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial.
Madhavan M; Ritchie AJ; Aboagye J; Jenkin D; Provstgaad-Morys S; Tarbet I; Woods D; Davies S; Baker M; Platt A; Flaxman A; Smith H; Belij-Rammerstorfer S; Wilkins D; Kelly EJ; Villafana T; Green JA; Poulton I; Lambe T; Hill AVS; Ewer KJ; Douglas AD
EBioMedicine; 2022 Nov; 85():104298. PubMed ID: 36229342
[TBL] [Abstract][Full Text] [Related]
5. A Case of Heart Transplantation for Fulminant Myocarditis After ChAdOx1 nCoV-19 Vaccination.
Kim SH; Lee SY; Kim GY; Oh JS; Kim J; Chun KJ; Ju MH; Lee CH; Song YJ; Na JY
J Korean Med Sci; 2022 Apr; 37(13):e104. PubMed ID: 35380028
[TBL] [Abstract][Full Text] [Related]
6. MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature.
Jarius S; Bieber N; Haas J; Wildemann B
J Neurol; 2022 Oct; 269(10):5198-5212. PubMed ID: 35737110
[TBL] [Abstract][Full Text] [Related]
7. Generalized Edema and Pseudothrombocytopenia After ChAdOx1 nCoV-19 COVID-19 Vaccination: A Case Report.
Bokel J; Mendes-de-Almeida DP; Martins-Gonçalves R; Palhinha L; Vizzoni AG; Correa DF; Brandão LGP; Bozza PT; Grinsztejn B
Front Public Health; 2022; 10():907652. PubMed ID: 35692333
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.
Menni C; May A; Polidori L; Louca P; Wolf J; Capdevila J; Hu C; Ourselin S; Steves CJ; Valdes AM; Spector TD
Lancet Infect Dis; 2022 Jul; 22(7):1002-1010. PubMed ID: 35405090
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study.
Wanlapakorn N; Suntronwong N; Phowatthanasathian H; Yorsaeng R; Vichaiwattana P; Thongmee T; Auphimai C; Srimuan D; Thatsanatorn T; Assawakosri S; Kanokudom S; Poovorawan Y
Hum Vaccin Immunother; 2022 Dec; 18(1):2029111. PubMed ID: 35209809
[TBL] [Abstract][Full Text] [Related]
10. Case reports of management of aplastic anemia after COVID-19 vaccination: a single institute experience in Taiwan.
Chen CY; Chen TT; Hsieh CY; Lien MY; Yeh SP; Chen CC
Int J Hematol; 2023 Jan; 117(1):149-152. PubMed ID: 36057889
[TBL] [Abstract][Full Text] [Related]
11. Herpes zoster following vaccination with ChAdOx1 nCoV-19 Coronavirus vaccine (recombinant).
Job AM; Sudhamani B; Mohan M; Mohanasundaram SN
Indian J Public Health; 2022; 66(1):83-85. PubMed ID: 35381724
[TBL] [Abstract][Full Text] [Related]
12. Recurrent Anterior Non-necrotizing Scleritis as an Adverse Event of ChAdOx1 nCoV-19 (Vaxzevria) Vaccine.
Hernanz I; Arconada C; López Corral A; Sánchez-Pernaute O; Carreño E
Ocul Immunol Inflamm; 2022 Jul; 30(5):1247-1249. PubMed ID: 35394853
[TBL] [Abstract][Full Text] [Related]
13. Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination.
Sheng WH; Chang SY; Lin PH; Hsieh MJ; Chang HH; Cheng CY; Yang HC; Pan CF; Ieong SM; Chao TL; Chen JP; Cheng SH; Chang SC
J Formos Med Assoc; 2022 Apr; 121(4):766-777. PubMed ID: 35305895
[TBL] [Abstract][Full Text] [Related]
14. Herpes simplex virus retinitis following ChAdOx1 nCoV- 19 (Covishield) vaccination for SARS CoV 2: A case report.
Singh J; More A; Shetty SB; Chaskar P; Sen A
Ocul Immunol Inflamm; 2022 Jul; 30(5):1282-1285. PubMed ID: 35587646
[TBL] [Abstract][Full Text] [Related]
15. Adverse effects following COVID-19 vaccination in Iran.
Babaee E; Amirkafi A; Tehrani-Banihashemi A; SoleimanvandiAzar N; Eshrati B; Rampisheh Z; Asadi-Aliabadi M; Nojomi M
BMC Infect Dis; 2022 May; 22(1):476. PubMed ID: 35585518
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study.
Cerqueira-Silva T; Andrews JR; Boaventura VS; Ranzani OT; de Araújo Oliveira V; Paixão ES; Júnior JB; Machado TM; Hitchings MDT; Dorion M; Lind ML; Penna GO; Cummings DAT; Dean NE; Werneck GL; Pearce N; Barreto ML; Ko AI; Croda J; Barral-Netto M
Lancet Infect Dis; 2022 Jun; 22(6):791-801. PubMed ID: 35366959
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults.
Niyomnaitham S; Quan Toh Z; Wongprompitak P; Jansarikit L; Srisutthisamphan K; Sapsutthipas S; Jantraphakorn Y; Mingngamsup N; Licciardi PV; Chokephaibulkit K
Hum Vaccin Immunother; 2022 Nov; 18(6):2091865. PubMed ID: 35816053
[TBL] [Abstract][Full Text] [Related]
18. Management of a severe bilateral pulmonary embolism as a complication of VITT following vaccination with AstraZeneca COVID-19 vaccine.
Elkoumy M; Schoen J; Loew A
BMJ Case Rep; 2022 May; 15(5):. PubMed ID: 35545306
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of intradermal administration of fractional dose CoronaVac
Chatsiricharoenkul S; Niyomnaitham S; Posen HJ; Toh ZQ; Licciardi PV; Wongprompitak P; Duangchinda T; Pakchotanon P; Chantima W; Chokephaibulkit K
Front Immunol; 2022; 13():1010835. PubMed ID: 36268028
[TBL] [Abstract][Full Text] [Related]
20. Adverse events following immunization with ChAdOx1 nCoV-19 and BBIBP-CorV vaccine: A comparative study among healthcare professionals of Nepal.
Rayamajhi S; Rafi MA; Tripathi N; Dongol AS; Pandey M; Rayamajhi S; Bhandari S; Shrestha P; Hasan MT; Hossain MG
PLoS One; 2022; 17(8):e0272729. PubMed ID: 35947626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
